http://www.biofortuna.com Just another WordPress weblog Fri, 07 Oct 2011 11:17:13 +0000 http://backend.userland.com/rss092 en Although we have no current vacancies, Biofortuna does plan to expand over the next year in the areas of R&D, Production, Sales, Bioinformatics, Marketing and Product Management; consequently, if you are interested in a job with a forward-thinking, exciting employer then we would be pleased to hold your CV and ... http://www.biofortuna.com/index.php/jobs/career-opportunities/ Biofortuna Ltd, a UK-based molecular diagnostics company, today announced that they have signed an exclusive distribution agreement with Abbott’s molecular diagnostics business, whereby Biofortuna will design, develop and manufacture a range of freeze-dried HLA-typing kits called SSPGo.  Financial terms have not been disclosed. Under the terms of the agreement, Abbott will ... http://www.biofortuna.com/index.php/news/biofortuna-announces-an-exclusive-distribution-agreement-with-abbott-for-its-freeze-dried-hla-typing-kits-in-the-transplantation-market/ Over 25 years experience in biotech working for Amersham International, ICI and Zeneca, in a variety of commercial and technical positions. Previously the CEO of the Life Science company Tepnel plc and Chief Executive of the VC backed start-up company DNA Research Innovations Ltd (DRI) which was acquired by Invitrogen ... http://www.biofortuna.com/index.php/staff-directors/simon-douglas/ Biofortuna Ltd, the UK based molecular diagnostics company specialising in its proprietary freeze-dried diagnostics, today announces the immediate appointment of Dr Simon Douglas as Chief Executive Officer. The move allows Dr Mike Bunce, who jointly held the position of CEO and CSO to focus as the CSO. Biofortuna Ltd has a ... http://www.biofortuna.com/index.php/news/biofortuna-ltd-announces-the-appointment-of-dr-simon-douglas-as-chief-executive-officer/ Biofortuna has raised £1 million ($1.6 million), which it will use to develop a market for its diagnostic genotyping products and new products. The funding, provided alongside Catapult Venture Managers, Merseyside Special Investment Fund and the company’s Non-Executive Directors, is part of a £1million funding package, which will be used to ... http://www.biofortuna.com/index.php/news/biofortuna-raises-1-6m/ UK-based molecular diagnostics company Biofortuna Limited has unveiled the world’s first complete freeze-dried HLA PCR kit in a move set to transform the transplantation market. The award-winning firm, led by internationally renowned HLA molecular immunologist Dr Mike Bunce, is revolutionising clinical testing methods with its proprietary freeze-dried ‘SSPGo’ technology. SSPGo is a ... http://www.biofortuna.com/index.php/news/biofortuna-heats-up-the-pcr-market/ SAN DIEGO (September 14, 2010) – TriLink BioTechnologies, Inc. (TriLink) announced that it has signed a licensing agreement with Biofortuna Ltd. (Biofortuna) for use of CleanAmp™ dNTPs in Biofortuna’s freeze dried in vitro diagnostic PCR kits. Biofortuna is developing a range of unique HLA diagnostic kits which will address the ... http://www.biofortuna.com/index.php/news/trilink-biotechnologies-inc-announces-license-agreement-with-biofortuna-ltd/ Prior to joining Biofortuna Harry was a Consultant offering business analysis services to the Pharmaceutical and Life Science sectors. Before this he was Director of Operations at London Genetics, a company providing pharmacogenomic research projects to the pharma and biotech industry. At DxS, a personalized medicine company, he was a ... http://www.biofortuna.com/index.php/staff-directors/harry-singh/ Geoff joins Biofortuna as Financial Director; Geoff is an experienced finance professional who has worked with various small, medium and large businesses including Altrix, Concateno, Paver Downes, Enterprise Care Group, Gemini Holdings and Novolytics. Email: geoff.orme@biofortuna.com http://www.biofortuna.com/index.php/staff-directors/geoff-orme/ David Whitcombe is an experienced biotech director who brings a wealth of experience in successfully developing quality diagnostics and in growing biotechnology companies. David was previously part of the successful founding team of DXS, a North West UK based Molecular Diagnostics company which sold to Qiagen in 2009 in a ... http://www.biofortuna.com/index.php/staff-directors/dr-david-whitcombe/